In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Hold rating on Cellectis SA (CLLS – Research Report), with a price target of $3.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yanan Zhu has given his Hold rating due to a combination of factors surrounding Cellectis SA’s recent performance and future prospects. The company’s first-quarter results showed a net loss per share that was slightly below market expectations, which may have contributed to a cautious outlook. Despite this, the company’s cash reserves are projected to sustain operations into the second half of 2027, indicating a stable financial position in the near term.
Additionally, Cellectis is making progress in its clinical trials, with key data readouts expected in the upcoming quarters. The ongoing collaboration with AstraZeneca also provides potential for future growth, as it involves the development of innovative therapies. However, the current uncertainties in clinical outcomes and market conditions may have led to a more conservative Hold rating, suggesting that while there is potential, investors should remain cautious and monitor upcoming developments closely.